| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 1997;29:45.)
© 1997 American Heart Association, Inc.
Research Articles (Issue 1, Part 1) |
Vascular Aldosterone in Genetically Hypertensive Rats
the Second Department of Internal Medicine (Y.T., I.M., S.I., K.F., H.H., T.Y., H.M.) and Department of Health Sciences (Y.T.), School of Medicine, Kanazawa University, and KKR Hokuriku Hospital (R.T.), Kanazawa, Japan.
Correspondence to Yoshiyu Takeda MD, Second Department of Internal Medicine, School of Medicine, Kanazawa University, 13-1 Takara-machi, Kanazawa 920, Japan.
We have reported that aldosterone is synthesized and cytochrome P450aldo mRNA exists in the vasculature. To clarify the pathophysiological role of vascular aldosterone in hypertension, we compared aldosterone production in the mesenteric arteries of stroke-prone spontaneously hypertensive rats (SHRSP) with that in Wistar-Kyoto rats (WKY). The expressions of mRNA of cytochrome P450aldo, mineralocorticoid receptor, and 
1 Na,K-ATPase in the mesenteric arteries were compared between the two groups. Aldosterone concentration in the perfusate of the vasculature was measured by radioimmunoassay after purification with high-performance liquid chromatography. Cytochrome P450aldo and mineralocorticoid receptor mRNA levels were quantified by Southern blot analysis of the products of reverse-transcribed polymerase chain reaction. Levels of 1 Na,K-ATPase mRNA were measured by Northern blot analysis. Vascular aldosterone and cytochrome P450aldo mRNA levels of 2-week-old SHRSP were significantly increased compared with those of age-matched WKY. However, vascular aldosterone in 4- and 9-week-old SHRSP did not differ from that in age-matched WKY. Expression levels of mineralocorticoid receptor mRNA in the vasculature of 4- and 9-week-old SHRSP were significantly increased compared with those in age-matched WKY. Concentrations of vascular 1 Na,K-ATPase mRNA of 2-, 4-, and 9-week-old SHRSP also were significantly higher than those in age-matched WKY. These results suggest that vascular aldosterone contributes to the pathophysiology of hypertension in SHRSP in the early stage.
Key Words: aldosterone • rats, inbred SHR • receptors, mineralocorticoid • Na+,K+-exchanging ATPase • RNA, messenger
This article has been cited by other articles:
 |
|
 |
|
  A. Karagiannis, K. Tziomalos, A. I Kakafika, V. G Athyros, F. Harsoulis, and D. P Mikhailidis Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas Endocr. Relat. Cancer, September 1, 2008; 15(3): 693 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M. Siragy and C. Xue Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats Exp Physiol, July 1, 2008; 93(7): 817 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Marcy and T. L. Ripley Aldosterone antagonists in the treatment of heart failure Am. J. Health Syst. Pharm., January 1, 2006; 63(1): 49 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. H. W. Tang, A. C. Parameswaran, A. P. Maroo, and G. S. Francis Aldosterone Receptor Antagonists in the Medical Management of Chronic Heart Failure Mayo Clin. Proc., December 1, 2005; 80(12): 1623 - 1630. [Abstract] [PDF]
|
|
|
|
 |
|
 J. M C Connell and E. Davies The new biology of aldosterone J. Endocrinol., July 1, 2005; 186(1): 1 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fiebeler, J. Nussberger, E. Shagdarsuren, S. Rong, G. Hilfenhaus, N. Al-Saadi, R. Dechend, M. Wellner, S. Meiners, C. Maser-Gluth, et al. Aldosterone Synthase Inhibitor Ameliorates Angiotensin II-Induced Organ Damage Circulation, June 14, 2005; 111(23): 3087 - 3094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Funder Cardiac Synthesis of Aldosterone: Going, Going, Gone... ? Endocrinology, November 1, 2004; 145(11): 4793 - 4795. [Full Text] [PDF]
|
|
|
|
|
|
E. P. Gomez-Sanchez, N. Ahmad, D. G. Romero, and C. E. Gomez-Sanchez Origin of Aldosterone in the Rat Heart Endocrinology, November 1, 2004; 145(11): 4796 - 4802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Vasan, J. C. Evans, M. G. Larson, P. W.F. Wilson, J. B. Meigs, N. Rifai, E. J. Benjamin, and D. Levy Serum Aldosterone and the Incidence of Hypertension in Nonhypertensive Persons N. Engl. J. Med., July 1, 2004; 351(1): 33 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. K Shieh, E. Kotlyar, and F. Sam Aldosterone and cardiovascular remodelling: focus on myocardial failure Journal of Renin-Angiotensin-Aldosterone System, March 1, 2004; 5(1): 3 - 13. [Abstract] [PDF]
|
|
|
|
|
|
B. Pitt, C. T Stier Jr, and S. Rajagopalan Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, September 1, 2003; 4(3): 164 - 168. [Abstract] [PDF]
|
|
|
|
|
|
N. J. Brown Eplerenone: Cardiovascular Protection Circulation, May 20, 2003; 107(19): 2512 - 2518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Rocha, A. E. Rudolph, G. E. Frierdich, D. A. Nachowiak, B. K. Kekec, E. A. G. Blomme, E. G. McMahon, and J. A. Delyani Aldosterone induces a vascular inflammatory phenotype in the rat heart Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1802 - H1810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Epstein, J. Almirall, T. Lopez, A. Chrysostomou, and G. Becker Spironolactone and ACE Inhibition in Chronic Renal Failure N. Engl. J. Med., February 7, 2002; 346(6): 456 - 457. [Full Text] [PDF]
|
|
|
|
|
|
G.-M. Wang, R.-S. Ge, S. A. Latif, D. J. Morris, and M. P. Hardy Expression of 11{beta}-Hydroxylase in Rat Leydig Cells Endocrinology, February 1, 2002; 143(2): 621 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Gomez-Sanchez and E. P. Gomez-Sanchez Cardiac Steroidogenesis--New Sites of Synthesis, or Much Ado About Nothing? J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5118 - 5120. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Florian, A. Dorrance, R. C. Webb, and S. W. Watts Mineralocorticoids upregulate arterial contraction to epidermal growth factor Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R878 - R886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Dorrance, H. L. Osborn, R. Grekin, and R. C. Webb Spironolactone reduces cerebral infarct size and EGF-receptor mRNA in stroke-prone rats Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2001; 281(3): R944 - R950. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Park and E. L. Schiffrin ETA Receptor Antagonist Prevents Blood Pressure Elevation and Vascular Remodeling in Aldosterone-Infused Rats Hypertension, June 1, 2001; 37(6): 1444 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rocha, C. T. Stier Jr., I. Kifor, M. R. Ochoa-Maya, H. G. Rennke, G. H. Williams, and G. K. Adler Aldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy Endocrinology, October 1, 2000; 141(10): 3871 - 3878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Takeda, T. Yoneda, M. Demura, I. Miyamori, and H. Mabuchi Cardiac Aldosterone Production in Genetically Hypertensive Rats Hypertension, October 1, 2000; 36(4): 495 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hatakeyama, S. Inaba, and I. Miyamori 11ß-Hydroxysteroid Dehydrogenase in Cultured Human Vascular Cells : Possible Role in the Development of Hypertension Hypertension, May 1, 1999; 33(5): 1179 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rocha, P. N. Chander, A. Zuckerman, and C. T. Stier Jr. Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats Hypertension, January 1, 1999; 33(1): 232 - 237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Takeda, S. Inaba, K. Furukawa, and I. Miyamori Renal 11ß-Hydroxysteroid Dehydrogenase in Genetically Salt-Sensitive Hypertensive Rats Hypertension, December 1, 1998; 32(6): 1077 - 1082. [Abstract] [Full Text] [PDF]
|
|